Annexon Inc. Reports Q2 2026 Results; Expands Vonaprument Phase 3 in GA

What Happened

• On August 12, 2026, Annexon, Inc. (ANNX) announced its financial results for the second quarter ended June 30, 2026 and issued business updates. The company also disclosed an expansion of its vonaprument Phase 3 program in geographic atrophy (GA), adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint and launching an open‑label extension study. These updates were communicated in press releases the company furnished with its Form 8‑K.

Key Details

• Filing date: August 12, 2026; quarter reported: Q2 ended June 30, 2026.
• Clinical program change: Vonaprument Phase 3 in GA will include a Month 24 dual primary endpoint in addition to the Month 15 primary endpoint.
• Program follow‑up: Company is launching an open‑label extension (OLE) study to provide continued access/longer‑term data for participants.
• Announcements were made via two press releases (Q2 results and the vonaprument program update) furnished with the Form 8‑K.

Why It Matters

• The Phase 3 design change (adding a Month 24 dual primary endpoint) increases the program’s follow‑up and could affect the timing and content of pivotal readouts and regulatory discussions — items material to valuation and milestone expectations.
• The open‑label extension can generate longer‑term safety and durability data and may affect patient retention and future data sets.
• Investors should review the company’s Q2 press release for financial details (cash position, R&D spending, guidance and near‑term milestones) and the vonaprument update for implications on trial timelines and regulatory strategy.